Close Menu

Personalis

Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs. 

Personalis will analyze samples from the study, evaluating the pharma company's novel therapy INVAC-1 either as a monotherapy or in combination with the TKI ibrutinib.

The company hopes to convert biopharma customers to increasingly comprehensive approaches, and intends to branch out further with blood-based exome sequencing next year.

The firm brought in $15.8 million during the quarter compared to $8.8 million a year ago, and beating Wall Street expectations.

The company will test samples from women treated with an investigational combination of AstraZeneca's PARP inhibitor olaparib and immunotherapy tremelimumab.

Invitae said this week that it completed its acquisition of Singular Bio on June 19.

The company is offering around 7.9 million shares of common stock at a price of $17 per share and is granting the underwriters an option to buy an additional 1.2 million shares.

The company expects to offer 6.7 million common shares at a maximum offering price of $16 per share.

FLX Bio will apply Personalis' ImmunoID Next platform as part of a Phase I/II clinical trial evaluating its FLX475 drug in cancer therapy.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.